P
Philip S. Insel
Researcher at University of California, San Francisco
Publications - 112
Citations - 8081
Philip S. Insel is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Cognitive decline & Alzheimer's disease. The author has an hindex of 39, co-authored 102 publications receiving 6305 citations. Previous affiliations of Philip S. Insel include United States Department of Veterans Affairs & University of Southern California.
Papers
More filters
Journal ArticleDOI
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
TL;DR: Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo, and this risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.
Journal ArticleDOI
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
TL;DR: Small statistical effect sizes on symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone.
Journal ArticleDOI
Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Paul K. Crane,Adam C. Carle,Laura E. Gibbons,Philip S. Insel,R. Scott Mackin,Alden L. Gross,Richard N. Jones,Shubhabrata Mukherjee,S. McKay Curtis,Danielle J Harvey,Michael Weiner,Dan M Mungas +11 more
TL;DR: This article developed and evaluated a composite memory score from the neuropsychological battery used in the Alzheimer's Disease (AD) Neuroimaging Initiative (ADNI) data to develop ADNI-Mem, which was as good as or better than all of the other scores at predicting conversion from MCI to AD.
Journal ArticleDOI
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment
Laura E. Gibbons,Adam C. Carle,R. Scott Mackin,Danielle J Harvey,Shubhabrata Mukherjee,Philip S. Insel,S. McKay Curtis,Dan M Mungas,Paul K. Crane +8 more
TL;DR: ADNI-EF appears to be a useful composite measure of EF in MCI, as good as or better than any of its composite parts, and was the strongest predictor of AD conversion.
Journal ArticleDOI
Plasma tau in Alzheimer disease
Niklas Mattsson,Henrik Zetterberg,Henrik Zetterberg,Henrik Zetterberg,Shorena Janelidze,Philip S. Insel,Ulf Andreasson,Erik Stomrud,Sebastian Palmqvist,David Baker,Cristina Tan Hehir,Andreas Jeromin,David Hanlon,Linan Song,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Oskar Hansson,Kaj Blennow,Kaj Blennow +19 more
TL;DR: Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia, and results do not support plasma tau as an AD biomarker in individual people.